Abbvie Inc ABBV

$285.64 +0.45 (0.16%)

Valuation

Market cap
503,871,680,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
26.20
Forward PE
20.43
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,631,800
Avg volume
4,659,582
Day's range
$282.30 – $286.77
Shares out
1,766,793,000
Stochastic %K
67%
Beta
0.24
Analysts
Strong Sell
Price target
$284.40

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

topstockalerts Oct 24, 2:19 AM
AbbVie shares could move 5% when the pharmaceutical company reports earnings on October 30 before the market opens, according to Bloomberg options data. The stock has exceeded its options-implied move in four of its last eight earnings reports, highlighting the potential for significant volatility around the results. Recent earnings reactions have varied. On July 31, shares fell 2.3% against an implied move of 4.2%, while the April 29 report resulted in a 0.6% decline versus an expected 4.8% move. On February 4, the stock dropped 3.0%, below the implied 3.8% move. Earlier reports produced larger swings. On October 31, 2025, shares fell 4.5% compared with an implied 3.7% move. On April 25, 2025, the stock gained 7.6% versus an expected 5.5%, while January 31 saw a 7.8% gain against an implied 3.8% move. Shares also rose 6.7% on October 30, 2024, exceeding the expected 3.7% move. $ABBV
0 replies
SQUEAKSBANDIT Oct 24, 12:28 AM
$ALDX how much does $ABBV have to pay if they opt in for both indications
0 replies
TopOptionAlert Oct 23, 11:40 PM
$ABBV NOV20 295C · still actionable Zone: $284 to $288 Invalidation: close under $280 Objectives: $291.50, then $300 The math: up 2.0% to the first objective and 4.9% to the second, against 2.1% risk on the invalidation, better than 2 to 1 to the second. Dear friend, picture a drug that used to mean a trip to the infusion clinic becoming a shot a patient gives at home, and that is exactly what AbbVie won from the FDA today for Skyrizi in Crohn's disease, which widens the patient pool and makes the drug easier to stay on. Goldman lifted the price it expects the stock to reach to $294 yesterday, and the 52 week high at $291.40 is now the only ceiling left in sight. This is a swing: we ride the catalyst runup into earnings on Oct 30 and let the breakout do the talking. P.S. Earnings print Oct 30 before the open, so this trade has a built in deadline.
0 replies
focafoca99 Oct 23, 7:50 PM
$ABBV rolled out FDA approval of SKYRIZI subcutaneous induction for Crohn's, enabling at-home start with an on-body injector. https://www.rapidticker.com/news/abbv-us-fda-approves-subcutaneous-induction-cbcc05
0 replies
RockyTSTH Oct 23, 7:41 PM
$ABBV AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease
0 replies
Rayvio_News_Filter Oct 23, 7:35 PM
$ABBV 🏥 The U.S. FDA approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease, expanding administration options with an on-body injector.
0 replies
55X_ROI_Q1_2026 Oct 23, 6:32 PM
$SLS $10K invested in SLS down here at $11.40 Per Share / $2.3B Market Cap - will be worth $100K to $200K the moment the GPS Phase 3 Results are Announced and the Market Sees the news: "Gps Immunotherapy more than Doubles Survival for AML Remission Patients." Imminently Due. its been 165 since the 78th event was announced May 11, while we await 2 events. $MRNA $ABBV $MRK
0 replies
Insight4u2004 Oct 23, 5:40 PM
$IOVA Don’t forget $ABBV !
1 replies